Actions
Pages
Subscribe for newsletter
Stories
Italian space logistics startup D-Orbit has raised $110 million for their satellite deployment and space operations business. The investment is led by Marubeni Corporation from Japan's industrial sector, with participation from various other investors.
D-Orbit provides last-mile satellite delivery, mission control services, and space waste management. The company's model involves a combination of software and hardware development and caters to both government and commercial space projects.
As a logistics provider for companies in the space industry, the company claims that its operational model saves 40% on costs and 85% on time by grouping multiple customers together and bulk-procuring around launches.
D-Orbit's founders, trained as engineers with expertise in space propulsion, flight dynamics, and aerodynamics, envision expanding their services to connect Mars, the asteroid belt, the moon, and Earth through a logistics network. The company also aims to contribute to the circular economy in space technology by addressing the growing issue of space debris through methods like decommissioning satellites and repurposing satellite parts in orbit.
Story
The U.S. Department of Veterans Affairs (VA) has committed to financing research into MDMA and psilocybin therapies for veteran mental health care.
This is a major change in how PTSD and depression are treated in veterans, leveraging the therapeutic potential of psychedelics for mental health conditions.
"Our nation's veterans deserve the very best care, and VA is constantly supporting innovations to deliver that," said VA Secretary Denis McDonough.
MDMA-based treatment for mental health and PTSD is becoming more mainstream. Lykos Therapeutics, formerly MAPS, recently raised $100 million to advance psychedelic research and applied for FDA approval in December.
Story
Moonwalk Biosciences, co-founded by CRISPR pioneer Feng Zhang and former Illumina CTO Alex Aravanis, has secured $57 million in funding to advance gene therapy with its epigenetic editing technology.
The gene therapy market, set to surge from $7.18 billion in 2024 to $24.67 billion by 2029, continues to innovate with Moonwalk's non-invasive epigenetic editing. This method, targeting epigenetic modifications over DNA alteration, provides safer, more effective treatments for chronic and aging-related diseases.
“Epigenetics is the software of the genome. While changes to the genome are irreversible, edits to the epigenome can be reprogrammed in different ways. Epigenetic changes determine whether genes are turned on or off, and can potentially reverse disease, broadening the therapeutic landscape to find potential cures previously thought impossible,” said Alex Aravanis, M.D., Ph.D., CEO and Co-Founder, Moonwalk Biosciences.
The next steps include clinical trials to validate the safety and efficacy of its epigenetic editing technique. As this technology advances, it could challenge the industry's belief that traditional gene editing, such as CRISPR-Cas9, is the only path forward for gene therapy.
Moonwalk's approach, utilizing AI for predicting epigenetic targets, leverages the body's natural regulation system, offering a nuanced approach to gene control. This resonates with the trend in biotechnology towards precision and personalization, moving away from one-size-fits-all solutions.
Story
Innovators
Scroll
Open
Close